Icure Pharmaceutical Incorporation (KOSDAQ:175250)
South Korea · Delayed Price · Currency is KRW 1,384.00
-42.00 (-2.95%)
At close: Nov 4, 2026
KOSDAQ:175250 Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 114,425 | 83,385 | 50,705 | 56,806 | 59,367 | 64,283 |
Revenue Growth | 101.68% | 64.45% | -10.74% | -4.31% | -7.65% | -28.69% |
Gross Profit Gross Profit Growth | 8,991 | 4,398 | 6,641 | 1,298 | -5,580 | -4,804 |
Operating Income Operating Income Growth | -10,202 | -18,333 | -15,969 | -27,605 | -27,087 | -30,119 |
Net Income Net Income Growth | -21,682 | -33,600 | 1,198 | -31,272 | -41,766 | -38,167 |
Earnings Per Share EPS Growth | -579.13 | -897.66 | 31.99 | -837.00 | -1793.00 | -1763.00 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Business Division Pharmaceutical Business Division Growth | 20,236 | 19,655 | 24,272 | 40,388 | 46,412 | 50,578 |
Cosmetics Division Cosmetics Division Growth | 94,189 | 63,729 | 26,434 | 16,418 | 12,955 | 13,705 |
Total Total Growth | 114,425 | 83,385 | 50,705 | 56,806 | 59,367 | 64,283 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 8,166 | 11,010 | 22,437 | 8,558 | 53,786 | 24,417 |
Total Debt Total Debt Growth | 25,200 | 27,655 | 40,440 | 74,015 | 87,009 | 74,186 |
Net Cash (Debt) Net Cash Growth | -17,034 | -16,645 | -18,003 | -65,457 | -33,224 | -49,769 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -454.97 | -444.58 | -480.86 | -1742.81 | -1426.23 | -2298.37 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -2,340 | -2,685 | -17,054 | -13,519 | -11,282 | -26,228 |
Capital Expenditures CapEx Growth | -3,886 | -5,110 | -2,023 | -2,225 | -4,197 | -5,701 |
Free Cash Flow Free Cash Flow Growth | -6,226 | -7,795 | -19,077 | -15,744 | -15,479 | -31,929 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 7.86% | 5.27% | 13.10% | 2.28% | -9.40% | -7.47% |
Operating Margin | -8.92% | -21.99% | -31.49% | -48.59% | -45.63% | -46.85% |
Pretax Margin | -20.69% | -42.34% | 6.89% | -57.00% | -72.58% | -60.41% |
Profit Margin | -18.95% | -40.29% | 2.36% | -55.05% | -70.35% | -59.37% |
FCF Margin | -5.44% | -9.35% | -37.62% | -27.72% | -26.07% | -49.67% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 56.63 | - | - | - |
Forward PE | - | 7.87 | 7.87 | 7.87 | 7.87 | 7.87 |
PS Ratio | 0.45 | 0.97 | 1.34 | 1.38 | 1.34 | 5.27 |